Business
GB Sciences Files Patents for Heart Disease and Chronic, Immunological, and Neuropathic Pain
GB Sciences Files Patents for Heart Disease and Chronic, Immunological, and Neuropathic Pain.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n\n\n\nGB Sciences Files Patents for Heart Disease and Chronic, Immunological, and Neuropathic Pain\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nGB Sciences Files Patents for Heart Disease and Chronic, Immunological, and Neuropathic Pain\nThe nonprovisional patent applications protect formulations for pain and heart disease therapies based on myrcene-containing complex mixtures.\nPR Newswire\nLAS VEGAS, June 25, 2018\n\n\n\nLAS VEGAS, June 25, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) has filed nonprovisional patent applications to protect its myrcene-containing complex mixtures (\"MCCC\") for the treatment of chronic pain and heart disorders. These new US and PCT international applications claim the benefit of GB Sciences' provisional application previously filed on May 22nd, 2017, supplying additional data from patch-clamp studies on individual cells that further support their claims. Novel pain treatments are a promising field of research and development given concerns regarding opioid usage and potential for abuse. The Company's novel pain formulations are also substantially free of delta-9 tetrahydrocannabinol (\"THC\"), which minimizes their potential for abuse. Pain represents an estimated health burden of between $560 and 650 billion dollars for chronic pain and between $17 and $20 billion dollars for immunological/neuropathic pain in the US alone. In addition, these novel cardiac formulations address the $316 billion-dollar cardiac therapy market in the US.\n\n\n \n \n\n \n\"GB Sciences' myrcene-containing complex mixtures for heart disease and chronic pain leverage powerful molecular synergies between specific complex formulations of active ingredients derived from the cannabis plants including many terpenes and minor cannabinoids,\" said Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences, Inc. \"Our formulations capture whole plant medicine's benefits, but they are further optimized and standardized. In preclinical studies, these complex mixtures have a greater therapeutic potential than the sums of the therapeutic effects of the indi...